ClinicalTrials.gg
RecruitingNCT07347925Updated Jan 16, 2026

Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF

An observational study in Heart Failure, sponsored by Future University in Egypt. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Future University in Egypt · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
140
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Heart Failure with a site in Egypt — 16 open to participants now, 21 under way, 2 of them phase 3. Heart Failure · Egypt.

Planned enrollment
9th of 17
140 · median 140
Started
2026
with 10 others
Observational
17 of 63
4 open now
Primary completion
2026-04
later than 7 of 20 live
Registered
51st of 63
by date

Among the 63 studies in Heart Failure with a site in Egypt, this one is the 9th largest by planned enrollment of the 17 observational ones that give a count, is one of 11 that started in 2026, is one of 17 observational ones, reaches primary completion later than 7 of the 20 other live ones, and was the 51st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 63 studies in Heart Failure with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Heart Failure with a site in Egypt, or all of them as a file.
02

Study summary

This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before hospital admission affects short-term health outcomes.

The study will compare two groups of participants: those who were already taking ARNI before coming to the hospital and those who were not. Information will be collected from medical records during the hospital stay, including heart-related events, kidney-related events, and how long participants stay in the hospital.

Some participants will also be followed for a short period after discharge. This study may help improve understanding of outcomes associated with ARNI use in people with heart failure in routine clinical care.

03

Conditions studied

  • Heart Failure

Keywords

  • Heart Failure
  • NYHA class
  • Sacubitril/Valsartan
  • Chronic kidney disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients with heart failure and reduced ejection fraction who are admitted to the cardiology wards at Mansoura University Hospital (MUH) during the study period. Participants include those who were already receiving ARNI therapy prior to hospital admission and those who were not, representing typical patients seen in clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >= 18 years, male or female EF \<40%

Exclusion criteria

Exclusion Criteria:

  • EF>40% Pregnancy or breastfeeding
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
140 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prehospital ARNI users

    Other: Prehospital ARNI use

  • Non-Prehospital ARNI users

    Other: No prehospital ARNI use

Interventions

  • OtherPrehospital ARNI use

    Participants who were using ARNI therapy before hospital admission

  • OtherNo prehospital ARNI use

    Participants who were not using ARNI therapy before hospital admission

06

What researchers measure

Primary outcomes

  1. In-hospital cardiac and renal events

    Time frame: 3 months

Secondary outcomes

  1. NYHA classification

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Apr 2026, 3 months later.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 3 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 16, 2026
StartEst.
Jan 10, 2026
Primary completionEst.
Apr 15, 2026
CompletionEst.
May 1, 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07347925
Responsible party
Mrwan Ayman Ahmed Eassa (MS Student, Clinical Pharmacy Department, Future University in Egypt, Future University in Egypt) — Principal investigator
First posted
Jan 16, 2026
Start date
Jan 10, 2026 (estimated)
Primary completion
Apr 15, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Jan 16, 2026
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion